137 related articles for article (PubMed ID: 17386970)
1. Human chorionic gonadotropin (hCG) and prevention of breast cancer.
Janssens JP; Russo J; Russo I; Michiels L; Donders G; Verjans M; Riphagen I; Van den Bossche T; Deleu M; Sieprath P
Mol Cell Endocrinol; 2007 Apr; 269(1-2):93-8. PubMed ID: 17386970
[TBL] [Abstract][Full Text] [Related]
2. Effects of recombinant human LH and hCG on serum and urine LH and androgens in men.
Handelsman DJ; Goebel C; Idan A; Jimenez M; Trout G; Kazlauskas R
Clin Endocrinol (Oxf); 2009 Sep; 71(3):417-28. PubMed ID: 19170708
[TBL] [Abstract][Full Text] [Related]
3. Hormonal approach to breast cancer prevention.
Russo IH; Russo J
J Cell Biochem Suppl; 2000; 34():1-6. PubMed ID: 10762007
[TBL] [Abstract][Full Text] [Related]
4. Human chorionic gonadotropin decreases proliferation and invasion of breast cancer MCF-7 cells by inhibiting NF-kappaB and AP-1 activation.
Rao ChV; Li X; Manna SK; Lei ZM; Aggarwal BB
J Biol Chem; 2004 Jun; 279(24):25503-10. PubMed ID: 15044447
[TBL] [Abstract][Full Text] [Related]
5. Endocrine modifications associated with final oocyte maturation with gonadotropin-releasing hormone agonists vs. human chorionic gonadotropin in women undergoing intrauterine insemination.
Díaz I; Guillén A; Pacheco A; Requena A; Garcia-Velasco JA
J Reprod Med; 2008 Jan; 53(1):33-9. PubMed ID: 18251359
[TBL] [Abstract][Full Text] [Related]
6. Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial.
Kubista E; Planellas Gomez JV; Dowsett M; Foidart JM; Pohlodek K; Serreyn R; Nechushkin M; Manikhas AG; Semiglazov VF; Hageluken CC; Singer CF
Clin Cancer Res; 2007 Jul; 13(14):4185-90. PubMed ID: 17634547
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of urinary and recombinant chorionic gonadotropin on oxidative stress responses in decidualizing human endometrial stromal cells.
Kajihara T; Tochigi H; Uchino S; Itakura A; Brosens JJ; Ishihara O
Placenta; 2011 Aug; 32(8):592-7. PubMed ID: 21641641
[TBL] [Abstract][Full Text] [Related]
8. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
9. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.
Dunn BK; Ford LG
Eur J Cancer Prev; 2007 Jun; 16(3):232-42. PubMed ID: 17415094
[TBL] [Abstract][Full Text] [Related]
10. Human chorionic gonadotropin as an angiogenic factor in breast cancer during pregnancy.
Michel RM; Aguilar JL; Arrieta O
Med Hypotheses; 2007; 68(5):1035-40. PubMed ID: 17112680
[TBL] [Abstract][Full Text] [Related]
11. hLH/hCG-receptor expression correlates with in vitro invasiveness in human primary endometrial cancer.
Noci I; Pillozzi S; Lastraioli E; Dabizzi S; Giachi M; Borrani E; Wimalasena J; Taddei GL; Scarselli G; Arcangeli A
Gynecol Oncol; 2008 Dec; 111(3):496-501. PubMed ID: 18829089
[TBL] [Abstract][Full Text] [Related]
12. Influence of chemotherapy to hormonal levels in postmenopausal breast cancer patients.
Pribylova O; Springer D; Svobodnik A; Kyr M; Zima T; Petruzelka L
Neoplasma; 2008; 55(4):294-8. PubMed ID: 18505339
[TBL] [Abstract][Full Text] [Related]
13. Clinical criteria as predictive factors of response to primary hormone therapy in locally advanced breast cancer.
Tiezzi DG; de Andrade JM; Marana HR; Garieri AP; de Paula Philbert PM
Breast J; 2009; 15(4):333-8. PubMed ID: 19496783
[TBL] [Abstract][Full Text] [Related]
14. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
15. Kalopanaxsaponin A inhibits PMA-induced invasion by reducing matrix metalloproteinase-9 via PI3K/Akt- and PKCdelta-mediated signaling in MCF-7 human breast cancer cells.
Park SK; Hwang YS; Park KK; Park HJ; Seo JY; Chung WY
Carcinogenesis; 2009 Jul; 30(7):1225-33. PubMed ID: 19420016
[TBL] [Abstract][Full Text] [Related]
16. Effects of follicle-stimulating hormone and human chorionic gonadotropin on gonadal steroidogenesis in two siblings with a follicle-stimulating hormone beta subunit mutation.
Lofrano-Porto A; Casulari LA; Nascimento PP; Giacomini L; Naves LA; da Motta LD; Layman LC
Fertil Steril; 2008 Oct; 90(4):1169-74. PubMed ID: 17961559
[TBL] [Abstract][Full Text] [Related]
17. Hyperglycosylated human chorionic gonadotropin and human chorionic gonadotropin free beta-subunit: tumor markers and tumor promoters.
Cole LA; Butler SA
J Reprod Med; 2008 Jul; 53(7):499-512. PubMed ID: 18720925
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
Søiland H; Skaland I; Varhaug JE; Kørner H; Janssen EA; Gudlaugsson E; Baak JP; Søreide JA
Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.
Alkner S; Bendahl PO; Fernö M; Nordenskjöld B; Rydén L;
Eur J Cancer; 2009 Sep; 45(14):2496-502. PubMed ID: 19535242
[TBL] [Abstract][Full Text] [Related]
20. Hormonal therapy for advanced breast cancer.
Rugo HS
Hematol Oncol Clin North Am; 2007 Apr; 21(2):273-91. PubMed ID: 17512449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
